Clinical Trials Logo
  1. Home
  2. Advanced Lung Cancer
  3. NCT06026111

Feasibility and Preliminary Efficacy of Exercise During Immunotherapy in Patients With Lung Cancer: The INHALE Trial — INHALE  

Advanced Lung Cancer Clinical Trial

Official title:
Feasibility and Preliminary Efficacy of Exercise During Immunotherapy in Patients With Lung Cancer: The INHALE Trial

Clinical Trial Summary

The purpose of this study is to determine whether a 12-week, home-based, virtually supervised exercise intervention is feasible and improves various health outcomes among individuals with advanced lung cancer receiving immunotherapy. The names of the study interventions involved in this study are: - High-intensity interval training (HIIT) (Home-based, virtually supervised, high intensity training in an interval fashion) - Moderate-intensity continuous training (MICT) (Home-based, virtually supervised, moderate intensity in a continuous fashion) - Usual care (UC)

Clinical Trial Description

This single-center, two-armed, pilot randomized controlled research study will assess feasibility and compare immune activities, cardiorespiratory fitness, physical function, and immunotherapy-related adverse events, and patient-reported outcomes between three groups - high-intensity exercise, moderate-intensity exercise, and usual care. Participants in this study will be randomly assigned to one of three groups: Group A High-intensity interval training (HIIT), Group B Moderate-intensity continuous training (MICT), or Group C Usual Care (UC). The HIIT and the MICT groups will receive virtually (Zoom) supervised home-based exercise training three sessions per week for 12 weeks. Randomization means that a participant is placed into a study group by chance. The research study procedures include screening for eligibility and study treatment including extensive evaluations of fitness and physical health, blood tests, and questionnaires/surveys. Participation in this research study is expected to last for up to 12 weeks. It is expected that about 30 people will take part in this research study. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06026111
Study type Interventional
Source Dana-Farber Cancer Institute
Contact Christina Dieli-Conwright, MPH, PhD
Phone 617-582-8321
Email ChristinaM_Dieli-Conwright@dfci.harvard.edu
Status Recruiting
Phase N/A
Start date December 8, 2023
Completion date April 30, 2025
View Details
See also
  Status Clinical Trial Phase
Completed NCT04575831 - Exercise, Nutrition, and Palliative Care in Advanced Lung Cancer (ENPAL) N/A
Completed NCT04069494 - Descriptors and Predictors of Burden and Information Needs
Terminated NCT03330834 - CAR-T Cell Immunotherapy for Advanced Lung Cancer Phase 1
Withdrawn NCT03004105 - MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC) Phase 2
Withdrawn NCT03501056 - Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Lung Cancer Phase 2
Not yet recruiting NCT05279521 - The Effect of Interventional Pulmonary Rehabilitation Exercise With Advanced Lung Cancer. N/A
Terminated NCT02768337 - Cambridge Brain Mets Trial 1 Phase 1/Phase 2
Completed NCT04672369 - A Study to Evaluate the Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced NSCLC Phase 1
Recruiting NCT03751592 - Phase Ib/IIa Studies of Chlorogenic Acid for Injection for Safety and Efficacy of Advanced Lung Cancer Phase 1/Phase 2
Not yet recruiting NCT05431569 - A Phase IIa Study to Evaluate the Efficacy and Safety of 6MW3211 in Patients With Advanced Lung Cancer Phase 2
Recruiting NCT06228209 - Tier - Palliative Care For Patients With Advanced Heart Failure or Cancer N/A
Completed NCT04672356 - A Study to Evaluate the Safety , Tolerability and Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced Lung Cancer Phase 1
Active, not recruiting NCT04670445 - Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer N/A
Not yet recruiting NCT06107894 - TIL Therapy for Patients With Advanced Solid Tumors Phase 1
Recruiting NCT06183762 - A Real-World Study of Treatment Patterns and Effectiveness in MET Mutation-Positive Advanced Lung Cancer
Recruiting NCT05664971 - JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer Phase 1/Phase 2
Recruiting NCT05815862 - Clinical Study of AL2846 Capsules in the Treatment of Advanced Lung Tumor and Advanced Ovarian Cancer Phase 2
Recruiting NCT05805956 - IMM2902 in Patients With Advanced Solid Tumors Expressing HER2 Phase 1/Phase 2
Recruiting NCT06106152 - WTX212A Monotherapy and in Combination With PD -1/PD-L1 Monoclonal Antibody Early Phase 1
Recruiting NCT05000684 - Study of JS004 Combined With Toripalimab for Advanced Lung Cancer Phase 1/Phase 2